<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35313473</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2451-9936</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of ophthalmology case reports</Title>
          <ISOAbbreviation>Am J Ophthalmol Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>First XEN implantation in Axenfeld- Rieger syndrome: A case report and literature review.</ArticleTitle>
        <Pagination>
          <StartPage>101486</StartPage>
          <MedlinePgn>101486</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101486</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajoc.2022.101486</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To present the first report of a XEN45 gel stent implantation in a female with Axenfeld-Rieger syndrome (ARS), a rare congenital anomaly caused by abnormal neural crest migration during early embryogenesis. This shows promise as new minimally invasive therapeutic option in the treatment of secondary glaucoma in ARS.</AbstractText>
          <AbstractText Label="OBSERVATIONS" NlmCategory="UNASSIGNED">A 31-year-old female with known sporadic ARS was evaluated and treated at the Edith Wolfson Medical Center in Holon, Israel. The vision in her right eye was hand motion and 20/25 in the left eye. In the left eye the intraocular pressure (IOP) was up to 31 mmHg under maximal tolerated treatment. She refused Trabeculectomy or Glaucoma Drainage Device (GDD) surgery, but agreed to Minimally Invasive Glaucoma Surgery (MIGS). A Xen device was implanted in uneventful surgery. 15 months post operatively her IOP is 8 mmHg.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">XEN implantation, when technically feasible, is a suitable procedure in ARS. This shows promise as new minimally invasive therapeutic option in the treatment of secondary glaucoma in ARS. This has particular significance as these patients often require surgery at a young age.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mendel</LastName>
            <ForeName>Liat</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Edith Wolfson Medical Center, 62 Halohamim st., Holon, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eremenko</LastName>
            <ForeName>Ron</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Edith Wolfson Medical Center, 62 Halohamim st., Holon, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naveh</LastName>
            <ForeName>Lilly Zborowski-</ForeName>
            <Initials>LZ</Initials>
            <AffiliationInfo>
              <Affiliation>Edith Wolfson Medical Center, 62 Halohamim st., Holon, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kalev-Landoy</LastName>
            <ForeName>Maya</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Edith Wolfson Medical Center, 62 Halohamim st., Holon, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Assuta HaShalom, 96 Yigal Alon st., Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Ophthalmol Case Rep</MedlineTA>
        <NlmUniqueID>101679941</NlmUniqueID>
        <ISSNLinking>2451-9936</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Axenfeld-Rieger syndrome</Keyword>
        <Keyword MajorTopicYN="N">Case report</Keyword>
        <Keyword MajorTopicYN="N">MIGS</Keyword>
        <Keyword MajorTopicYN="N">Secondary childhood glaucoma</Keyword>
        <Keyword MajorTopicYN="N">XEN implant</Keyword>
      </KeywordList>
      <CoiStatement>All authors have no financial disclosures: LM, RE, LN, MKL.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35313473</ArticleId>
        <ArticleId IdType="pmc">PMC8933667</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ajoc.2022.101486</ArticleId>
        <ArticleId IdType="pii">S2451-9936(22)00232-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zamora E.A., Salini B. Axenfeld-rieger syndrome. https://www.ncbi.nlm.nih.gov/books/NBK538504 Available at.</Citation>
        </Reference>
        <Reference>
          <Citation>Alward W.L. Axenfeld-Rieger syndrome in the age of molecular genetics. Am J Ophthalmol. 2000;130(1):107–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11004268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumer Z., Bach-Holm D. Axenfeld–Rieger syndrome and spectrum of PITX2 and FOXC1 mutations. Eur J Hum Genet. 2009;17(12):1527–1539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2987033</ArticleId>
            <ArticleId IdType="pubmed">19513095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shields M.B., Buckley E., Klintworth G.K., Thresher R. Axenfeld-Rieger syndrome. A spectrum of developmental disorders. Surv Ophthalmol. 1985;29(6):387–409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3892740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song W., Hu X. The rare Axenfeld–Rieger syndrome with systemic anomalies: a case report and brief review of literature. Medicine (Baltim) 2017;96(33)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5571701</ArticleId>
            <ArticleId IdType="pubmed">28816964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shields M.B. Axenfeld-Rieger syndrome: a theory of mechanism and distinctions from the iridocorneal endothelial syndrome. Trans Am Ophthalmol Soc. 1983;81:736–784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1312467</ArticleId>
            <ArticleId IdType="pubmed">6676983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal A.K., Pehere N. Early-onset glaucoma in Axenfeld–Rieger anomaly: long-term surgical results and visual outcome. Eye. 2016;30(7):936–942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4941068</ArticleId>
            <ArticleId IdType="pubmed">27055677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hohberger B., Welge-Luen U.C., Lammer R. ICE-syndrome: a case report of implantation of a microbypass Xen gel stent after DMEK transplantation. J Glaucoma. 2017;26(2):e103–e104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27841796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green W., Lind J.T., Sheybani A. Review of the xen gel stent and InnFocus MicroShunt. Curr Opin Ophthalmol. 2018;29(2):162–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29319544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zepeda E.M., Branham K., Moroi S.E., Bohnsack B.L. Surgical outcomes of Glaucoma associated with Axenfeld-Rieger syndrome. BMC Ophthalmol. 2020;20(1):172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7193416</ArticleId>
            <ArticleId IdType="pubmed">32357855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Gregorio A., Lind J., Sheybani A. XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice. Clin Ophthalmol. 2018;12:773–782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933334</ArticleId>
            <ArticleId IdType="pubmed">29750009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souzeau E., Siggs O.M., Zhou T., et al.  Glaucoma spectrum and age-related prevalence of individuals with FOXC1 and PITX2 variants. Eur J Hum Genet. 2017;25(11):1290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5643974</ArticleId>
            <ArticleId IdType="pubmed">29023440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharpe R., Pham G., Chang P. Comparison of ab interno XEN gelatin stent vs trabeculectomy with Mitomycin C: a retrospective study. J Curr Glaucoma Pract. 2020;14(3):87–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8028032</ArticleId>
            <ArticleId IdType="pubmed">33867756</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
